Cellectar Biosciences (CLRB) Stock Rating Upgraded by ValuEngine

Cellectar Biosciences (NASDAQ:CLRB) was upgraded by ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Friday, February 2nd.

Separately, Zacks Investment Research raised shares of Cellectar Biosciences from a “sell” rating to a “hold” rating in a research report on Tuesday, October 17th.

Shares of Cellectar Biosciences (CLRB) opened at $1.15 on Friday. The stock has a market cap of $18.11, a price-to-earnings ratio of -1.07 and a beta of 0.85. Cellectar Biosciences has a 1 year low of $1.06 and a 1 year high of $3.07.

Cellectar Biosciences (NASDAQ:CLRB) last released its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.01). analysts predict that Cellectar Biosciences will post -0.96 EPS for the current year.

A hedge fund recently raised its stake in Cellectar Biosciences stock. Virtu KCG Holdings LLC boosted its stake in Cellectar Biosciences Inc (NASDAQ:CLRB) by 90.5% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 64,864 shares of the biopharmaceutical company’s stock after acquiring an additional 30,808 shares during the period. Virtu KCG Holdings LLC owned about 0.48% of Cellectar Biosciences worth $106,000 as of its most recent SEC filing. 1.71% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: “Cellectar Biosciences (CLRB) Stock Rating Upgraded by ValuEngine” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/02/11/cellectar-biosciences-clrb-rating-increased-to-sell-at-valuengine.html.

About Cellectar Biosciences

Cellectar Biosciences, Inc, formerly Novelos Therapeutics, Inc, is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Cellectar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply